JP2019194190A5 - - Google Patents

Download PDF

Info

Publication number
JP2019194190A5
JP2019194190A5 JP2019102325A JP2019102325A JP2019194190A5 JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5 JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019102325 A JP2019102325 A JP 2019102325A JP 2019194190 A5 JP2019194190 A5 JP 2019194190A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
cancer
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019102325A
Other languages
English (en)
Japanese (ja)
Other versions
JP6794496B2 (ja
JP2019194190A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019194190A publication Critical patent/JP2019194190A/ja
Publication of JP2019194190A5 publication Critical patent/JP2019194190A5/ja
Priority to JP2020187991A priority Critical patent/JP6985486B2/ja
Application granted granted Critical
Publication of JP6794496B2 publication Critical patent/JP6794496B2/ja
Priority to JP2021191088A priority patent/JP7335310B2/ja
Priority to JP2023133133A priority patent/JP7650923B2/ja
Priority to JP2025038864A priority patent/JP2025102800A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019102325A 2011-10-28 2019-05-31 癌幹細胞特異的分子 Active JP6794496B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020187991A JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011237438 2011-10-28
JP2011237438 2011-10-28
JP2012091142 2012-04-12
JP2012091142 2012-04-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017228927A Division JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020187991A Division JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子

Publications (3)

Publication Number Publication Date
JP2019194190A JP2019194190A (ja) 2019-11-07
JP2019194190A5 true JP2019194190A5 (https=) 2020-03-12
JP6794496B2 JP6794496B2 (ja) 2020-12-02

Family

ID=48167907

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子
JP2019102325A Active JP6794496B2 (ja) 2011-10-28 2019-05-31 癌幹細胞特異的分子
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013540843A Active JP6291254B2 (ja) 2011-10-28 2012-10-26 癌幹細胞特異的分子
JP2017228927A Active JP6580112B2 (ja) 2011-10-28 2017-11-29 癌幹細胞特異的分子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020187991A Active JP6985486B2 (ja) 2011-10-28 2020-11-11 癌幹細胞特異的分子
JP2021191088A Active JP7335310B2 (ja) 2011-10-28 2021-11-25 癌幹細胞特異的分子
JP2023133133A Active JP7650923B2 (ja) 2011-10-28 2023-08-17 癌幹細胞特異的分子
JP2025038864A Pending JP2025102800A (ja) 2011-10-28 2025-03-12 癌幹細胞特異的分子

Country Status (4)

Country Link
US (3) US20140302511A1 (https=)
EP (2) EP2772268B8 (https=)
JP (7) JP6291254B2 (https=)
WO (1) WO2013062083A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
DK2817620T3 (en) * 2012-02-22 2016-09-05 Verik Bio Inc IMMUNTERY TREATMENT SYSTEM FOR TUMOR FORMATION AND PROGRESSION
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
MX2015017852A (es) * 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
US10883994B2 (en) * 2014-06-25 2021-01-05 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells markers and use of same for diagnosis and treatment
KR101779147B1 (ko) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
JP2016028569A (ja) * 2014-07-16 2016-03-03 学校法人慶應義塾 がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、miR−34aの発現量を低下させる方法及びがん幹細胞増殖抑制剤
EP3394107A1 (en) * 2015-12-22 2018-10-31 AbbVie Stemcentrx LLC Novel anti-tnfsf9 antibodies and methods of use
EP3604522B1 (en) 2017-03-28 2022-07-13 Keio University Human tissue stem cell and use thereof
KR102857853B1 (ko) * 2018-08-08 2025-09-09 추가이 세이야쿠 가부시키가이샤 암 조직 또는 암 조직과 유사한 조직의 배양 방법
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5573924A (en) * 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
EP0962467A4 (en) 1996-09-26 2002-10-30 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002220265A1 (en) 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
JP3753321B2 (ja) 2000-12-01 2006-03-08 財団法人実験動物中央研究所 異種細胞の生着、分化および増殖に適したマウスの作出方法、該方法により作出されたマウスならびにそのマウスの用途
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
WO2003104401A2 (en) * 2002-06-05 2003-12-18 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CA2525909A1 (en) 2003-05-16 2004-11-25 Kyowa Hakko Kogyo Co., Ltd. Novel stem cell derived from adult tissue and use thereof
JP2005035943A (ja) 2003-07-16 2005-02-10 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制剤
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
WO2005035740A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 無血清馴化したゲノム改変細胞
JP2005206508A (ja) * 2004-01-22 2005-08-04 Chemo Sero Therapeut Res Inst 悪性腫瘍細胞増殖抑制抗体
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2006039671A2 (en) 2004-09-29 2006-04-13 Central Institute For Experimental Animals Gene markers of tumor metastasis
WO2006051405A2 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
US20090081221A1 (en) 2004-11-15 2009-03-26 Kirin Beer Kabushiki Kaisha Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method
JP5122441B2 (ja) * 2005-04-19 2013-01-16 シアトル ジェネティックス, インコーポレイテッド ヒト化抗cd70結合剤およびその使用
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2009502156A (ja) * 2005-07-26 2009-01-29 プロキュア・セラピューティクス・リミテッド 幹細胞マーカー
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
CA2628255C (en) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070220621A1 (en) 2005-10-31 2007-09-20 Clarke Michael F Genetic characterization and prognostic significance of cancer stem cells in cancer
EP1792979A1 (en) 2005-12-01 2007-06-06 Stiftung Caesar Center of Advanced European Studies and Research Cell culture system for the enrichment and expansion of stem cells
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
WO2007124125A2 (en) * 2006-04-21 2007-11-01 Stowers Institute For Medical Research Methods of identifying stem cells in normal and cancerous tissues and related progeny cells
WO2007132883A1 (ja) 2006-05-17 2007-11-22 Yokohama City University 肝臓癌の鑑別、疾患ステージの判定又は予後の予測方法及びキット
WO2007145901A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
CN101506352B (zh) 2006-08-11 2013-05-29 达沃斯Ao研究所 鉴别和选择定向分化为特异类型的干细胞以获得均质干细胞群
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
EP2076587A4 (en) 2006-09-11 2009-12-09 Univ Florida ISOLATION, EXPANSION AND USE OF TUMOR STAMMING CELLS
GB2442059A (en) 2006-09-19 2008-03-26 Ist Superiore Sanita Test for cancer of the gastrointestinal tract
CN103396486A (zh) 2006-10-12 2013-11-20 中外制药株式会社 使用抗ereg抗体的癌症的诊断和治疗
JP2008102012A (ja) 2006-10-19 2008-05-01 Kanazawa Univ 癌幹細胞の同定および単離方法
CA2675521C (en) 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
JP2008182912A (ja) 2007-01-29 2008-08-14 Nippon Kayaku Co Ltd 癌幹細胞の培養方法、および癌幹細胞
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2008149803A1 (ja) 2007-06-06 2008-12-11 The University Of Tokyo 表面抗原マーカーを用いた急性リンパ性白血病における癌幹細胞の分離同定方法
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
EP2188367A4 (en) 2007-08-10 2010-10-27 Whitehead Biomedical Inst HORMON'S TREATIVE TISSUE CULTURE SYSTEM AND USES THEREOF
US20100287638A1 (en) 2007-10-01 2010-11-11 The Hospital For Sick Children Neural tumor stem cells and methods of use thereof
WO2009064301A1 (en) * 2007-11-15 2009-05-22 The Johns Hopkins University Methods for detecting and monitoring circulating cancer stem cells
SG186660A1 (en) 2007-12-14 2013-01-30 Chugai Pharmaceutical Co Ltd Novel method for specimen preparation, which ensures preservation of tissue morphology and nucleic acid quality
EP2271941B1 (en) 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2009135181A2 (en) * 2008-05-02 2009-11-05 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010009121A2 (en) 2008-07-15 2010-01-21 University Of Florida Research Foundation, Inc. Colon stem cells associated with colitis and colorectal cancer and methods of use
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
AU2010221159B2 (en) * 2009-03-06 2015-11-26 Humanigen, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
AU2010231575B2 (en) * 2009-03-30 2013-09-12 Edimer Biotech S.A. Preparation of isolated agonist anti-EDAR monoclonal antibodies
AR076344A1 (es) * 2009-04-20 2011-06-01 Genentech Inc Metodo de terapia complementaria contra el cancer
TW201105347A (en) * 2009-04-28 2011-02-16 Chugai Pharmaceutical Co Ltd Pharmaceutical compositions for maintenance therapy containing HLA class I-recognizing antibody as the active ingredient
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
WO2011027308A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
EP2517555A4 (en) 2009-12-25 2014-09-24 Chugai Pharmaceutical Co Ltd SEARCHING AND SCREENING METHOD FOR A TARGET MOLECULE OF A CANCER WITH A NON-MENTAL ANIMAL MODEL WITH A NO-CANCER LINE OF TRANSPLANTED LINE
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
JP6230789B2 (ja) 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
KR101463182B1 (ko) * 2011-01-13 2014-11-21 연세대학교 산학협력단 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2772268B8 (en) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US10504315B2 (en) 2013-08-05 2019-12-10 Ncr Corporation Clamping of media items

Similar Documents

Publication Publication Date Title
JP2019194190A5 (https=)
JP6603685B2 (ja) クロストリジウム・ディフィシレの主要な外毒素TcdA及びTcdBに対する中和抗体
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
JP2019527706A5 (https=)
JP2009539380A5 (https=)
TW201427664A (zh) Tec家族激酶抑制劑佐劑療法
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
ES2839456T3 (es) Proteína 2 que contiene el dominio del esperma móvil y del cáncer
JP2014524746A5 (https=)
RU2014138039A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2018523686A5 (https=)
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
CN111372606A (zh) 增强atp释放作用
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
JP2017113019A5 (https=)
CN110698558B (zh) 一种tpbg抗体及其制备方法、其偶联物和应用
Raeisi et al. Application of recombinant antibodies for treatment of Clostridioides difficile infection: current status and future perspective
WO2014151606A4 (en) Methods of treating pancreatic cancer
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
JP2014223083A5 (https=)
CN111278992A (zh) 用抗egfr抗体治疗癌症的组合物和方法
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
EP4243827A1 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR20200143385A (ko) Mospd2와, t 세포 또는 nk 세포 특이적 분자에 대한 2중 특이적 항체